Charting the Future of Alzheimer’s Care: Breakthroughs, Trials, and Prevention

Major Highlights from the AD/PD 2025 Conference

The AD/PD conference, held in 2025, was a landmark event showcasing global momentum in Alzheimer’s research. With a strong focus on amyloid- and tau-targeting therapies, it became clear that the future of AD care lies in disease modification and precision medicine.

Among the most impactful data came from Eisai, whose Eisai AD/PD congress materials detailed updates on lecanemab. The antibody therapy, now approved for early Alzheimer’s, showed continued promise in delaying cognitive deterioration and improving daily functioning. With a growing database of real-world outcomes, Eisai emphasized the need for early intervention and biomarker-based patient selection.

Innovative Oral Therapies: Spotlight on AR1001

Oral therapies are gaining traction in the AD landscape. A notable example is AR1001 Alzheimer’s, an investigational PDE5 inhibitor developed by Aribio. Unlike traditional antibody therapies, AR1001 works by boosting neuronal signaling and cerebral blood flow—offering a novel mechanism of action.

Encouraging results from Phase 2 trials led to a global Phase 3 study, enrolling a diverse patient population. Aribio’s research is making waves, with Aribio Alzheimer’s treatment news drawing attention across biotech and neurology sectors.

Prevention Takes Center Stage in 2025

A key theme at this year’s conference was prevention. Emerging practices in Alzheimer’s prevention 2025 are increasingly focused on detecting Alzheimer’s before clinical symptoms appear. Experts discussed combining genetic screening, digital tools, and lifestyle changes to reduce risk—an approach gaining traction across both clinical and consumer health spaces.

Studies show that managing sleep, cardiovascular health, and mental stimulation can reduce the risk or delay onset. These insights are informing new standards of care in geriatric and primary care practices worldwide.

Bridging the Gap Between Research and Real-World Access

One of the greatest challenges in implementing groundbreaking Alzheimer’s therapies is accessibility. High costs, limited biomarker testing availability, and insurance constraints create barriers for many patients. Innovations in care delivery, including mobile infusion clinics and shared neurology-primary care models, are being piloted to close the gap.

In parallel, patient advocacy and regulatory bodies are pushing for broader inclusion in trials to ensure new treatments reflect real-world populations. As we push forward, Alzheimer’s disease (AD) therapeutics must not only advance scientifically but become equitably accessible.

Looking Ahead

The field of Alzheimer’s research has never been more dynamic. Whether it’s Eisai’s biologics or Aribio’s oral drugs, a wide range of innovations are now closer than ever to impacting daily care. With an equal focus on prevention and access, the trajectory is promising. For millions affected by AD, this progress signals more than science—it’s a path toward real change.